Article in Science (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Xingwu Zhou *Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-5977-2185
Xiang Ling *Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-5431-844X
Xiaoqi SunDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-0752-1928
Ziye WanDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Tobias DwyerDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.
Timothy C MooreDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-5709-7259
Quguang LiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0004-7523-1791
Hannah E DobsonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1246-880X
Qi WuDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-2550-3769
Xiangbo KongCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0002-4289-3172
Fang XieDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Xinran AnDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Jingyao GanDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Kaikai WangDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0009-4266-5979
Young Seok ChoDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1338-3170
Wang GongDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katherine DongDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0001-5264-6298
Jie ZhangDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9941-1568
Mariko TakahashiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-2465-7907
Cheng XuDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1000-733X
Swetha KodamasimhamDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0000-8965-7313
Jie XuCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0001-9452-2878
Vilma Yuzbasiyan-GurkanDepartment of Microbiology, Genetics, and Immunology, Michigan State University, East Lansing, MI, USA.
Steven B ChinnDepartment of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI, USA.
Anna SchwendemanDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-8023-8080
Sharon C GlotzerBiointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-7197-0085
Yu Leo LeiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9868-9824
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-2238-2372
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Restoring the Immunogenicity of Head and Neck CancerR01DE026728 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yu Leo Lei, James J. Moon · 2018 to 2026
$4.3M
Engineered Nano-formulations for STING ActivationR01DE031951 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yu Leo Lei, James J. Moon · 2022 to 2026
$3.1M
New Engineering Strategy for Harnessing Immune System against Head and Neck CancerR01DE030691 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEI, YU LEO, MOON, JAMES J. · 2021 to 2025
$2.9M
Biomaterials for modulating the gut microbiome for immune activationR01CA271799 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Deepak Nagrath · 2022 to 2026
$2.7M
Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral PremalignancyU01DE033330 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Steven Bennett Chinn, Yu Leo Lei · 2023 to 2026
$2.7M
Novel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6M
Novel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5M
Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune ActivationR44CA281497 · NCI · SAROS THERAPEUTICS INC · PI JOHNSON, RICHARD · 2023 to 2024
$2.0M
Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine DepotsR01EB036493 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Peter M Tessier · 2025 to 2026
$1.2M
Engineering Metal Ion-Immunity Crosstalk for MetalloimmunotherapyDP2AI192719 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Xiaoqi Kevin Sun · 2025 to 2026
Natural systems use metal ions to form ordered structures that regulate biological processes, inspiring the rational design of nanotherapeutics. The cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway drives antitumor immunity but has been difficult to activate systemically owing to poor pharmacology and toxicity. Here, we report CRYSTAL, a structurally ordered intermetallic nanoparticle for potent systemic STING activation. CRYSTAL self-assembles from manganese ions intercalated with cyclic dinucleotides, enabling precise structural control. At an ultralow intravenous dose (0.003 milligrams per kilogram), CRYSTAL activated STING in mice, dogs, and nonhuman primates without cytokine release syndrome. CRYSTAL induced robust tumor regression in advanced murine and rabbit models, remodeled immunosuppressive environments, and promoted host STING-dependent CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Intermetallic nanoassemblies potentiate systemic STING activation. · full record | OpenQuestion